Core Viewpoint - Aquestive Therapeutics, Inc. announced an inducement grant for Dr. Matthew Greenhawt, Chief Medical Officer, under its 2022 Equity Inducement Plan, approved by the Compensation Committee [1][2]. Group 1: Inducement Grant Details - Dr. Greenhawt will receive 75,000 Restricted Stock Units (RSUs) and 50,000 non-qualified common stock options, with grants scheduled for March 9, 2026 [2]. - The RSUs and Options will vest 25% after the first and second anniversaries of the grant date, and 50% on the third anniversary, contingent on continued employment [2]. - The Options will have a ten-year term with an exercise price equal to the closing price of the common stock on the grant date [2]. Group 2: Company Overview - Aquestive is a pharmaceutical company focused on innovative science and delivery technologies to improve patients' lives [3]. - The company is a leader in delivering medications via oral film and operates as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO) [3]. - It manufactures four commercialized products for licensees globally and has a library of over 20 epinephrine prodrugs for allergy and dermatological indications [3].

分组1 - The company, Aquestive Therapeutics, is advancing medicines to improve patients' lives through innovative science and delivery technologies [2] - It operates as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO) [2] - The company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents [2] 分组2 - The company is advancing Anaphylm™ (dibutepinephrine) sublingual film for severe allergic reactions, including anaphylaxis [2] - AQST-108 (epinephrine prodrug) topical gel is being developed for various dermatological conditions, including alopecia areata [2] - The AdrenaVerse™ platform contains a library of over 20 epinephrine prodrugs for potential allergy and dermatological indications [2] 分组3 - Dr. Greenhawt will receive an equity award of 75,000 Restricted Stock Units and 50,000 non-qualified common stock options under the 2022 Equity Inducement Plan [1] - The equity awards will vest 25% after each of the first and second anniversaries of the grant date, and 50% on the third anniversary [1] - The awards were approved by the independent Compensation Committee as a material inducement for Dr. Greenhawt's acceptance of employment [1]

Core Insights - Aquestive Therapeutics, Inc. is participating in four upcoming investor conferences in March 2026, showcasing its commitment to engaging with investors and stakeholders [1] Company Overview - Aquestive is a pharmaceutical company focused on improving patients' lives through innovative science and delivery technologies [2] - The company is a leader in oral film medication delivery and operates as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO) [2] - Headquartered in New Jersey, the company has U.S.-based manufacturing facilities in Indiana and is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents [2] - The company utilizes proprietary technologies like PharmFilm® and has a library of over 20 epinephrine prodrugs within its AdrenaVerse™ platform, targeting various allergy and dermatological indications [2] Product Development - Aquestive is advancing Anaphylm™ (dibutepinephrine) sublingual film for treating severe allergic reactions, including anaphylaxis [2] - The company is also developing AQST-108 (epinephrine prodrug) topical gel for potential dermatological conditions, including alopecia areata [2] Upcoming Events - Management will be available for one-on-one meetings at the TD Cowen 46th Annual Health Care Conference on March 3rd [6] - A fireside chat is scheduled for March 9th at the Leerink Partners Global Healthcare Conference 2026, with additional one-on-one meetings available [6] - A presentation will take place on March 10th at the Citizens Life Sciences Conference, along with one-on-one meetings [6] - Management will also be available for one-on-one meetings on March 11th at the Barclays 28th Annual Global Healthcare Conference [6]

Company Overview - Aquestive Therapeutics, Inc. is a pharmaceutical company focused on advancing medicines to improve patients' lives through innovative science and delivery technologies [3] - The company operates as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO) for licensees, with headquarters in New Jersey and manufacturing facilities in Indiana [3] - Aquestive is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents, utilizing proprietary technologies like PharmFilm® [3] Upcoming Events - The management team will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, with a presentation scheduled for February 26 at 12 pm ET [1][2] - A webcast of the presentation will be available on the company's website, with a replay accessible for 30 days following the event [2] Product Development - The company is advancing its AdrenaVerse™ platform, which includes a library of over 20 epinephrine prodrugs aimed at various allergy and dermatological indications [3] - Current product developments include Anaphylm™ (dibutepinephrine) sublingual film for severe allergic reactions, including anaphylaxis, and AQST-108 (epinephrine prodrug) topical gel for dermatological conditions like alopecia areata [3]

Core Viewpoint - Aquestive Therapeutics has appointed Dr. Matthew Greenhawt as Chief Medical Officer to support the resubmission of the Anaphylm™ New Drug Application (NDA) and advance its clinical pipeline [1][2][3] Company Leadership and Expertise - Dr. Greenhawt is an internationally recognized expert in allergy and immunology, bringing extensive clinical, research, and advocacy experience to the company at a critical time [2][4] - The appointment is seen as a strong addition to the leadership team, with Dr. Greenhawt's expertise expected to be invaluable for FDA approval efforts [3] Product Development - Anaphylm™ (dibutepinephrine) is a sublingual film designed for the emergency treatment of anaphylaxis, which is expected to be the first oral medication for severe allergic reactions if approved by the FDA [7] - The product is designed to be user-friendly, dissolving on contact without the need for water or swallowing, and is compact enough to be carried easily [7] Company Background - Aquestive Therapeutics focuses on advancing medicines through innovative science and delivery technologies, operating as both a product developer and a Contract Development and Manufacturing Organization (CDMO) [8] - The company has a portfolio that includes four commercialized products and is advancing multiple product candidates, including Anaphylm and AQST-108 for various indications [8]

Core Viewpoint - Aquestive Therapeutics is making strategic leadership changes to support the potential launch of Anaphylm™, a novel epinephrine product, and to enhance its development pipeline [1][2][4] Leadership Changes - Dr. Matthew Davis has been appointed as Chief Development Officer, bringing over 20 years of experience in drug development and medical leadership [2][3] - Dr. Gary Slatko returns as interim Chief Medical Officer, with over three decades of experience in regulatory science and drug safety [3] - Peter Boyd has been promoted to Chief People Officer, having led various functions within the company since 2013 [4][5] Product Development - Anaphylm™ (dibutepinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug candidate designed for the rescue treatment of severe allergic reactions [7] - If approved by the FDA, Anaphylm would be the first oral medication for anaphylaxis, with a unique delivery method that does not require water or swallowing [7] Company Overview - Aquestive Therapeutics focuses on advancing medicines through innovative science and delivery technologies, with a portfolio that includes four commercialized products [8] - The company collaborates with pharmaceutical firms to develop new molecules using proprietary technologies like PharmFilm® [8]

Core Insights - Aquestive Therapeutics, Inc. is hosting a live fireside chat on November 6, 2025, focusing on its product candidate Anaphylm™ (dibutepinephrine) Sublingual Film, discussing regulatory progress and commercial readiness [1][2] Company Overview - Aquestive Therapeutics is a pharmaceutical company dedicated to improving patients' lives through innovative science and delivery technologies, developing orally administered products to deliver complex molecules [5] - The company has four commercialized products marketed by its licensees globally and collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies like PharmFilm® [5] Product Details - Anaphylm™ (dibutepinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug that is designed to be administered without water or swallowing, making it user-friendly [4] - If approved by the FDA, Anaphylm would be the first oral medication for the rescue treatment of severe allergic reactions, including anaphylaxis, with its trade name conditionally approved [4]

Core Insights - Aquestive Therapeutics is advancing its product candidate Anaphylm™ (dibutepinephrine) sublingual film for the treatment of severe allergic reactions, including anaphylaxis, with multiple presentations scheduled at the 2025 ACAAI Annual Meeting [1][2] Company Overview - Aquestive Therapeutics focuses on innovative science and delivery technologies to improve patient lives through the development of orally administered products [4] - The company has four commercialized products and collaborates with other pharmaceutical companies to bring new molecules to market using proprietary technologies like PharmFilm® [4] Product Details - Anaphylm™ is a polymer matrix-based epinephrine prodrug that is small, lightweight, and dissolves on contact without the need for water or swallowing [3] - If approved by the FDA, Anaphylm would be the first oral medication for the rescue treatment of severe allergic reactions, with its trade name conditionally approved [3]

Core Insights - Aquestive Therapeutics, Inc. will report its third quarter results for the period ending September 30, 2025, and provide business updates on November 5, 2025 [1] - A conference call for investors is scheduled for November 6, 2025, at 8:00 a.m. ET, with a live webcast available on the company's website [2] Company Overview - Aquestive is a pharmaceutical company focused on advancing medicines through innovative science and delivery technologies, aiming to improve patients' lives [3] - The company has four commercialized products marketed by its licensees globally and is the exclusive manufacturer of these products [3] - Aquestive is developing a late-stage proprietary product candidate for severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel for dermatological conditions like alopecia areata [3]

Core Viewpoint - Aquestive Therapeutics has announced that the FDA has determined that an advisory committee meeting is not required for the approval of Anaphylm™ (dibutepinephrine) Sublingual Film, with a target action date set for January 31, 2026 [1][7]. Product Overview - Anaphylm has the potential to be the first FDA-approved, non-invasive, orally delivered epinephrine product for treating severe allergic reactions, including anaphylaxis [2][3]. - The product is designed as a thin, dissolvable film that is placed under the tongue, offering a device-free and needle-free option for patients at risk of severe allergic reactions [2][3]. - Anaphylm is similar in size to a postage stamp, weighs less than an ounce, and begins to dissolve upon contact, requiring no water or swallowing for administration [4]. Clinical Development - Eleven clinical studies have been completed, totaling 967 administrations (840 single-dose and 127 repeat-dose) for adults and children over 30 kg [3]. - The development program includes a novel trial for oral allergy syndrome, demonstrating Anaphylm's real-world effectiveness [3]. Company Positioning - The company is well-positioned for the launch of Anaphylm, supported by recent financing activities totaling $160 million, which will facilitate outreach to healthcare providers, caregivers, and patients post-FDA approval [3]. - Aquestive Therapeutics is focused on advancing medicines through innovative science and delivery technologies, with four commercialized products marketed globally [5].